Article Sidebar
Views PDF: 535
SERUM NT-pro BNP CONCENTRATIONS IN PATIENTS WITH HEART FAILURE DUE TO HYPERTENSION
Main Article Content
Abstract
Research objectives: To determine the variation in serum NT-pro BNP concentrations and the relationship between serum NT-pro BNP concentrations with some clinical and subclinical indicators in patients with heart failure due to hypertension. Subjects and research methods: Cross-sectional descriptive studies that were performed on 120 patients with heart failure due to hypertension to survey the concentration of serum NT-pro BNP. Results: (1) The mean concentration of serum NT-pro BNP of patients with heart failure due to hypertension in the stage A group was 2168,92 ± 2884.87pg/ml, the stage B group was 2826,2 ± 1743 pg/ml, the stage C group is 11137,83 ± 8058 pg/ml, the stage D group is 16213,51 ± 10944,03 pg/ml (p <0,05); (2) the concentration of serum NT-pro BNP has a strong positive correlation with heart failure stages (according to AHA/ACC-2008) (r = 0.63; p <0.05); (3) There was a correlation between the concentration of serum NT-pro BNP with NYHA degree of heart failure (r = 0.53; p <0.05)and (4) There has been no correlation between the concentration of serum NT-pro BNP with: BMI, GFR and Hematocrit. Conclusion: The concentration of serum NT-pro BNP were elevated in patients with heart failure due to hypertension and it positively correlate with the stage of heart failure according to AHA/ACC-2008 and degree of heart failure according to NYHA.
Article Details
Keywords
serum NT-pro BNP, heart failure, hypertension
References
2. Austin W., Bhala V. (2015), “Correlation and prognostic utility of BNP and its amino-terminal fragment in patients with chronic kidney disease”, American J Clin Pathol. 126: p. 506-512.
3. Abdulle, A.M., et al. (2007), “Plasma N terminal pro-brain natriuretic peptide levels and its determinants in a multi-ethnic population”, J Hum Hypertens. 21: p. 647-653.
4. Bayés, A., G.M. Santaló, B.E. Zapico (2004), “N-terminal probrain natriuretic peptide in the emergency diagnosis and in-hospital monitoring of patients with dysapnea and ventricualar dysfuntion”, European Journal of Heart Failure, p. 301-308.
5. Dickstein, K., A. Cohen-Solal, G. Filippatos (2008), “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008”, Eur J Heart Fail. 10: p. 933-989.
6. Nielsen, O.W., et al. (2003), “Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population”, J Am Coll Cardiol. 41: p. 113-120.
7. Januzzi, J.L., et al. (2015), “The N-terminal NT-pro BNP investigation of dyspnea in the emergency department (PRIDE) study”, Am J Cardiol. 95: p. 948-954.
8. Zaphiriou A, R.S., Murray-Thomas T, Mendez G, (2005), “The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study”, Eur J Heart Fail. 7: p. 537-541.